Practice question

Answer the question and get instant feedback.

HardNeurologyMultiple SclerosisNICE Technology appraisal TA312 on Alemtuzumab

A 32-year-old woman has relapsing-remitting multiple sclerosis. She experiences recurrent relapses despite first-line disease-modifying therapy. According to NICE, which drug could be considered a second-line disease-modifying therapy?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.